From FLOW to translational positioning in chronic kidney disease: mechanistic complementarity of SGLT2 inhibitors and GLP-1 receptor agonists. — VialBase Research

Summary

Chronic kidney disease sits at the center of the cardio-kidney-metabolic continuum and carries substantial residual cardiovascular and kidney risk. This translational review takes the FLOW trial — which established hard kidney-outcome evidence for once-weekly semaglutide in type 2 diabetes with CKD — as its starting point and asks how GLP-1 receptor agonists and SGLT2 inhibitors should be positioned together. Rather than treating one as a simple add-on to the other, the authors synthesize evidence around mechanistic complementarity, arguing the two classes act on largely distinct but convergent pathways.

Key Findings

• The FLOW trial (Evaluate Renal Function With Semaglutide Once Weekly) established hard kidney-outcome evidence for semaglutide in type 2 diabetes with chronic kidney disease.
• Whether that renal benefit represents a broader GLP-1RA class effect, rather than a semaglutide-specific effect, remains unresolved.
• SGLT2 inhibitors predominantly provide proximal-tubular and hemodynamic offloading, coupled with fasting-mimetic metabolic reprogramming that may improve oxygen-stress balance and cellular housekeeping.
• GLP-1RAs predominantly support an immune-vascular repair program by dampening sterile inflammation, preserving endothelial integrity, and limiting fibrotic amplification.
• The two classes’ pathways appear to converge at mitochondrial homeostasis, autophagy, and barrier stability; the authors argue the most useful current implication is a phenotype-aware framing of residual risk, not a fixed prescribing algorithm.

Relevance to Semaglutide

For semaglutide specifically, this review situates the FLOW trial as the anchor of the GLP-1 renal-outcome evidence base and lays out a mechanistic rationale for why semaglutide’s kidney benefit may be complementary to — not redundant with — SGLT2-inhibitor therapy. The authors’ framing (immune-vascular repair for GLP-1RAs versus tubular and hemodynamic offloading for SGLT2 inhibitors) helps explain how semaglutide could add value on top of established CKD therapy. It also flags an open question directly relevant to the class: whether FLOW’s semaglutide result generalizes to other GLP-1 receptor agonists such as Tirzepatide, which remains unresolved.

Citation

Tian X, Ma X, Song E, et al. From FLOW to translational positioning in chronic kidney disease: mechanistic complementarity of SGLT2 inhibitors and GLP-1 receptor agonists. Translational research : the journal of laboratory and clinical medicine. 2026. doi:10.1016/j.trsl.2026.07.008.

See Also

• Parent compound: Semaglutide
• Tirzepatide